Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of an oncology consultation, reflecting coverage of Context Therapeutics’ CTIM-76 Phase 1 data and its potential role in platinum-resistant ovarian cancer treatment.
Pharma & Biotech

Why CTIM-76’s early ovarian cancer data could sharpen interest in CLDN6 T cell engagers

Find out how CTIM-76’s early Phase 1 data could shape CLDN6 T cell engager development in platinum-resistant ovarian cancer.

Read More
Medical Devices & Diagnostics

IceCure expands its U.S. ProSense footprint as breast cryoablation moves beyond clinical trials

Discover whether IceCure’s 70% ProSense installation growth can turn breast cryoablation into a scalable alternative to surgery.

Read More
Representative image: A pediatric diabetes specialist reviews glucose data during an infusion visit as Sanofi’s Tzield expands into newly diagnosed stage 3 type 1 diabetes care.
Pharma & Biotech

Why Sanofi’s Tzield expansion changes the treatment window for type 1 diabetes

Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.

Read More
Representative image: Alkermes’ alixorexton narcolepsy type 2 study highlights the potential of orexin receptor therapy to improve daytime wakefulness as Phase 3 testing examines dosing, safety and broader clinical benefit.
Pharma & Biotech

Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus

Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.

Read More
Representative image: A neurological researcher reviews advanced brain scans as uniQure prepares a potential FDA filing for AMT-130, its experimental gene therapy designed to slow Huntington’s disease progression.
Pharma & Biotech

FDA accepts uniQure’s AMT-130 filing strategy after months of regulatory uncertainty

Explore why the FDA reopened uniQure’s AMT-130 approval path and what evidence, surgical and confirmatory trial risks remain before review.

Read More
Representative image: Corcept Therapeutics has resubmitted the relacorilant New Drug Application for Cushing’s syndrome, reopening FDA scrutiny of efficacy, trial design and liver safety evidence.
Pharma & Biotech

Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains

Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.

Read More
Representative image: Researchers use artificial intelligence and machine learning to design tumour-targeting multispecific antibodies, reflecting the LabGenius Therapeutics and LG Chem collaboration aimed at improving precision and safety in solid tumour treatment.
Pharma & Biotech

LabGenius-LG Chem deal tests whether AI can improve solid-tumour treatment precision

Discover how LabGenius and LG Chem aim to use AI-designed multispecific antibodies to reduce solid-tumour toxicity and reshape oncology R&D.

Read More
Pharma & Biotech

Zydus Lifesciences’ Assertio merger signals a bigger push beyond generics into U.S. oncology

Find out how Zydus Lifesciences’ Assertio merger could reshape its U.S. oncology supportive-care strategy and Rolvedon growth.

Read More
Medical Devices & Diagnostics

Hologic wins key Siemens patent fight as breast imaging market enters sharper phase

Find out how Hologic’s patent victory against Siemens Healthineers could reshape breast cancer detection technology and medtech competition.

Read More
Pharma & Biotech

Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?

Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.

Read More